comprehensive -WSS

comprehensive

author：focus 2025-09-07 11:15:47 - browse：15679

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Covid isolation guidance eased by the CDC

Wikipedia

WSS

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Clinical trials giant ICON acquires HumanFirst

Clinical trials giant ICON acquires HumanFirst

How to address the problem of discarded donor organs

Study: New antibiotic targets gonorrhea as well as last existing drug

International team creates first chimeric human

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Heart attack and stroke risk calculators need revising

Medical device lobby: We're tired of waiting on Medicare coverage

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Scientists unlock the key to scar

Guidelines to prevent youth baseball injuries need more muscle

RSV vaccines may be linked to small increased risk of developing GBS

Continuity nursing helped my family in our darkest PICU moments

Medical device lobby: We're tired of waiting on Medicare coverage

Bright Health sells Medicare Advantage business to Molina

10 million people disenrolled from Medicaid over past six months

entertainment

Medicare will require more price transparency from hospitals

Medical device lobby: We're tired of waiting on Medicare coverage

White House calls on federal agencies to crack down on AI abuses

Ambulance rides for just $100? Advisers want major billing fixes

The new shift in health care is toward less care

Abortion clinic in Cancun will cater to Americans

hotspot

Wikipedia

focus

focus